Article info
PDFClinical and epidemiological research
Extended report
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
- Correspondence to Dr A Finckh, Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 Av Beau-Sejour, 1211 Geneva 14, Switzerland; axel.finckh{at}hcuge.ch
Citation
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Publication history
- Accepted April 20, 2009
- First published May 4, 2009.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Web Only Data 69/2/387
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Finckh et al 2010 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.